<table border="0" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr stylecode="Botrule">
<td colspan="5" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Table 1: Drugs that may have their plasma concentrations increased by itraconazole</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Drug Class </content>
</td>
<td stylecode="Rrule" valign="middle"> <content stylecode="bold">Contraindicated </content>
</td>
<td stylecode="Rrule" valign="middle"> <content stylecode="bold">Not Recommended </content>
</td>
<td stylecode="Rrule" valign="middle"> <content stylecode="bold">Use with Caution </content>
</td>
<td stylecode="Rrule" valign="middle"> <content stylecode="bold">Comments</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">              <content stylecode="italics">Under no circumstances is the drug to be coadministered with</content>
<br/>
<content stylecode="italics">itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.</content>
</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="italics">It is recommended that the use of the </content>
<content stylecode="italics">drug be avoided during and up to two weeks after discontinuation of</content>
<br/>
<content stylecode="italics">treatment with itraconazole, unless the benefits outweigh the potentially </content>
<content stylecode="italics">increased risks of side effects. If</content>
<br/>
<content stylecode="italics">coadministration cannot be avoided,</content>
<content stylecode="italics">clinical monitoring for signs or </content>
<content stylecode="italics">symptoms of increased or prolonged</content>
<br/>
<content stylecode="italics">effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed </content>
<content stylecode="italics">necessary. When appropriate, it is </content>
<content stylecode="italics">recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</content>
<br/>
</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="italics">Careful monitoring is recommended when the drug is coadministered with </content>
<content stylecode="italics">itraconazole. Upon coadministration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the </content>
<content stylecode="italics">interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</content>
<br/>
</td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Alpha Blockers</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> tamsulosin</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Analgesics</td>
<td stylecode="Rrule" valign="middle"> methadone</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">              alfentanil,<br/>buprenorphine IV and sublingual,<br/>fentanyl,<br/>oxycodone,<br/>sufentanil</td>
<td align="justify" stylecode="Rrule" valign="middle">              <content stylecode="bold">Methadone: </content>The potential increase in plasma concentrations of methadone when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>.<br/>
<content stylecode="bold">Fentanyl: </content>The potential increase in plasma concentrations of fentanyl when coadministered with Itraconazole Capsules may increase the risk of potentially fatal respiratory depression.<br/>
<content stylecode="bold">Sufentanil: </content>No human pharmacokinetic data of an interaction with itraconazole are available. In vitro data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with Itraconazole Capsules.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Antiarrhythmics</td>
<td stylecode="Rrule" valign="middle">              disopyramide,<br/>dofetilide,<br/>dronedarone,<br/>quinidine</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> digoxin</td>
<td align="justify" stylecode="Rrule" valign="middle">              <content stylecode="bold">Disopyramide, dofetilide,</content>
<br/>
<content stylecode="bold">dronedarone, quinidine: </content>The potential increase in plasma concentrations of these drugs when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QTc prolongation.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Antibacterials</td>
<td align="justify" stylecode="Rrule" valign="middle">              telithromycin, in<br/>subjects with severe<br/>renal impairment or<br/>severe hepatic impairment<br/>
</td>
<td stylecode="Rrule" valign="middle"> rifabutin</td>
<td stylecode="Rrule" valign="middle"> telithromycin</td>
<td stylecode="Rrule" valign="middle">
<content stylecode="bold">Telithromycin:</content> The potential<br/>increase in plasma concentrations of telithromycin in subjects with severe renal impairment or severe hepatic impairment, when coadministered with<br/>Itraconazole Capsulesmay increase the risk of serious cardiovascular events including QT prolongation and torsade de pointes.<br/>
<br/>
<content stylecode="bold">Rifabutin: </content>See also under ‘Drugs that may decrease itraconazole   plasma concentrations’</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">              Anticoagulants and<br/>Antiplatelet Drugs</td>
<td stylecode="Rrule" valign="middle"> ticagrelor</td>
<td stylecode="Rrule" valign="middle">apixaban, rivaroxaban</td>
<td stylecode="Rrule" valign="middle">              coumarins,<br/>cilostazol,<br/>dabigatran</td>
<td align="justify" stylecode="Rrule" valign="middle">              <content stylecode="bold">Ticagrelor: </content>The potential increase in plasma concentrations of ticagrelor may increase the risk of bleeding.<br/>
<content stylecode="bold">Coumarins: </content>Itraconazole Capsules may enhance the anticoagulant effect of coumarin-like drugs, such as warfarin.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Anticonvulsants</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> carbamazepine</td>
<td stylecode="Rrule" valign="middle"> </td>
<td align="justify" stylecode="Rrule" valign="middle">              <content stylecode="bold">Carbamazepine: </content>
<content stylecode="italics">In vivo </content>studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of Itraconazole Capsules and carbamazepine may inhibit the metabolism of carbamazepine.See also under ‘Drugs that may decrease itraconazole plasma<br/>concentrations’.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Antidiabetics</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">repaglinide,saxagliptin<br/>
</td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Antihelmintics and<br/>Antiprotozoals</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> praziquantel</td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Antimigraine Drugs</td>
<td stylecode="Rrule" valign="middle">ergot alkaloids, such as<br/>dihydroergotamine,<br/>ergometrine<br/>(ergonovine),<br/>ergotamine,<br/>methylergometrine<br/>(methylergonovine)</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> eletriptan</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="bold">Ergot Alkaloids: </content>The potential increase in plasma concentrations of ergot alkaloids when coadministered with<br/>Itraconazole Capsules  may increase the risk of ergotism, ie. a risk for vasospasm potentially leading to cerebral ischemia and/or ischemia of the extremities.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Antineoplastics</td>
<td stylecode="Rrule" valign="middle"> irinotecan</td>
<td stylecode="Rrule" valign="middle">axitinib, dabrafenib, dasatinib, ibrutinib, nilotinib, sunitinib,trabectedin<br/>
</td>
<td stylecode="Rrule" valign="middle">bortezomib, busulphan,  docetaxel,  erlotinib, gefitinib, imatinib,  ixabepilone,  lapatinib,  ponatinib,  trimetrexate,  vinca alkaloids<br/>
</td>
<td stylecode="Rrule" valign="middle">
<content stylecode="bold">Irinotecan: </content>The potential increase in plasma concentrations of irinotecan when coadministered with Itraconazole Capsules may increase the risk of potentially fatal adverse events.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Antipsychotics,<br/>Anxiolytics and<br/>Hypnotics</td>
<td stylecode="Rrule" valign="middle">lurasidone,<br/>oral midazolam,<br/>pimozide,<br/>triazolam</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">alprazolam,aripiprazole,buspirone,diazepam,haloperidol,midazolam IV,perospirone,quetiapine,ramelteon,risperidone<br/>
</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="bold">Midazolam, triazolam</content>:Coadministration of<br/>Itraconazole Capsules and oral<br/>midazolam, or triazolam may<br/>cause several-fold increases in plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.<br/>
<content stylecode="bold">Pimozide: </content>The potential increase in plasma concentrations of pimozide when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Antivirals</td>
<td stylecode="Rrule" valign="middle">  </td>
<td stylecode="Rrule" valign="middle"> simeprevir</td>
<td stylecode="Rrule" valign="middle">maraviroc,indinavir,ritonavir,saquinavir</td>
<td stylecode="Rrule" valign="middle">
<content stylecode="bold">Indinavir, ritonavir: </content>See also under ‘Drugs that may increase itraconazole plasma<br/>concentrations’.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Beta Blockers</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> nadolol</td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Calcium Channel<br/>Blockers</td>
<td stylecode="Rrule" valign="middle">felodipine,nisoldipine<br/>
</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">other dihydropyridines,verapamil<br/>
</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="bold">Calcium channel blockers </content>can have a negative inotropic effect which may be additive to those of itraconazole. The potential increase in plasma concentrations of calcium channel blockers when<br/>co-administered with Itraconazole Capsules may increase the risk of congestive heart failure.<br/>
<content stylecode="bold">Dihydropyridines: </content>Concomitant administration of Itraconazole Capsules may cause several-fold increases in plasma concentrations of dihydropyridines. Edema has been reported in patients concomitantly receiving Itraconazole Capsules and<br/>dihydropyridine calcium channel blockers.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Cardiovascular<br/>Drugs, Miscellaneous</td>
<td stylecode="Rrule" valign="middle">Ivabradine,<br/>             ranolazine</td>
<td align="justify" stylecode="Rrule" valign="middle">              aliskiren, sildenafil, for the treatment of pulmonary hypertension<br/>
</td>
<td stylecode="Rrule" valign="middle">              bosentan, riociguat <br/>
</td>
<td align="justify" stylecode="Rrule" valign="middle">
<content stylecode="bold">Ivabradine</content>: The potential increase in plasma concentrations of ivabradine when coadministered with Itraconazole Capsules may increase the risk of ivabradine-related adverse events, such as atrial fibrillation, bradycardia, sinus arrest and heart block. <br/>
<content stylecode="bold">Ranolazine: </content>The potential<br/>increase in plasma concentrations of ranolazine when coadministered with<br/>Itraconazole Capsules may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Diuretics</td>
<td stylecode="Rrule" valign="middle"> eplerenone</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">
<content stylecode="bold">Eplerenone: </content>The potential<br/>increase in plasma concentrations f eplerenone when coadministered with<br/>Itraconazole Capsules  may increase the risk of hyperkalemia and hypotension.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Gastrointestinal<br/>Drugs</td>
<td stylecode="Rrule" valign="middle"> cisapride</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> aprepitant</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="bold">Cisapride: </content>The potential increase in plasma concentrations of<br/>cisapride when oadministered<br/>with Itraconazole Capsules may increase the risk of serious cardiovascular events including QTc prolongation.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Immunosuppressants</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle">everolimus,<br/>temsirolimus</td>
<td stylecode="Rrule" valign="middle">budesonide,ciclesonide,cyclosporine,dexamethasone,fluticasone,methylprednisolone,rapamycin (also known as sirolimus),tacrolimus<br/>
</td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">Lipid Regulating<br/>Drugs</td>
<td stylecode="Rrule" valign="middle">lovastatin,<br/>simvastatin</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> atorvastatin</td>
<td stylecode="Rrule" valign="middle">The potential increase in plasma concentrations of atorvastatin,lovastatin, and simvastatin when coadministered with Itraconazole Capsules may increase the risk of skeletal muscle toxicity,including rhabdomyolysis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Respiratory Drugs</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> salmeterol</td>
<td stylecode="Rrule" valign="middle"> </td>
<td stylecode="Rrule" valign="middle"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> Urological Drugs</td>
<td stylecode="Rrule" valign="middle">              fesoterodine, in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, solifenacin, in subjects with severe renal impairment or moderate to severe hepatic impairment <br/>
</td>
<td stylecode="Rrule" valign="middle">              darifenacin, vardenafil<br/>
</td>
<td stylecode="Rrule" valign="middle">Fesoterodine, oxybutynin,  sildenafil, for the treatment of erectile dysfunction, solifenacin, tadalafil, tolterodine<br/> <br/> <br/>
</td>
<td stylecode="Rrule" valign="middle">              <content stylecode="bold">Fesoterodine</content>: The potential increase in plasma concentrations of the fesoterodine active metabolite may be greater in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, which may lead to an increased risk of adverse reactions.<br/>
<content stylecode="bold">Solifenacin</content>: The potential increase in plasma concentrations of solifenacin in subjects with severe renal impairment or moderate to severe hepatic impairment, when coadministered with Itraconazole Capsules may increase the risk of serious cardiovascular events including QT prolongation.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="middle"> Other</td>
<td stylecode="Rrule" valign="middle">colchicine, in subjects<br/>with renal or hepatic<br/>impairment</td>
<td align="justify" stylecode="Rrule" valign="middle">              colchicines, conivaptan, tolvaptan <br/>
</td>
<td stylecode="Rrule" valign="middle">cinacalcet,<br/>
</td>
<td stylecode="Rrule" valign="middle">
<content stylecode="bold">Colchicine: </content>The potential increase in plasma concentrations of<br/>colchicine when coadministered<br/>with Itraconazole Capsules may increase the risk of potentially fatal adverse <br/>events.<br/>
<br/>
<br/>
<content stylecode="bold">Conivaptan and Tolvaptan:</content> A safe and effective dose of either conivaptan or tolvaptan has not been established when coadministered with Itraconazole Capsules.<br/> <br/> <br/>
</td>
</tr>
</tbody>
</table>